Pediatric Gastrointestinal Outcomes During the Post-Acute Phase of COVID-19: Findings from RECOVER Initiative from 29 Hospitals in the US

Dazheng Zhang, Ronen Stein, Yiwen Lu, Ting Zhou, Yuqing Lei, Lu Li, Jiajie Chen, Jonathan Arnold, Michael J. Becich, Elizabeth A. Chrischilles, Cynthia H. Chuang, Dimitri Christakis, Daniel Fort, Carol Geary, Mady Hornig, Rainu Kaushal, David Liebovitz, Abu Saleh Mohammad Mosa, Hiroki Morizono, Parsa Mirhaji, Jennifer L. Dotson, Claudia Pulgarin, Marion R. Sills, Srinivasan Suresh, David A. Williams, Robert N. Baldassano, Christopher B. Forrest, Yong ChenmedRxiv 2024 · DOI

Abstract

In the post-acute and chronic phases of COVID-19, the risk of gastrointestinal (GI) symptoms and disorders is significantly increased for pediatric patients. This study, utilizing data from the RECOVER initiative across 29 US hospitals, quantifies these risks and identifies key demographic and clinical factors associated with long-term GI sequelae.

Introduction

Post-Acute Sequelae of SARS-CoV-2 (PASC), commonly known as "Long COVID," has been extensively documented in adult populations. However, its manifestation in children remains less understood, particularly regarding the gastrointestinal (GI) system. While clinicians have observed lingering GI symptoms in pediatric patients, large-scale evidence comparing these outcomes to uninfected controls over extended periods has been scarce.

This study addresses this knowledge gap by investigating the incidence of GI symptoms and disorders in a massive cohort of over 1.5 million children. By distinguishing between the post-acute phase (28 to 179 days post-infection) and the chronic phase (180 to 729 days post-infection), the researchers aimed to determine the longevity and evolution of these complications in the pediatric population.

Methodology

The researchers conducted a retrospective cohort study using the NIH Researching COVID to Enhance Recovery (RECOVER) Initiative database. The study population included 1,576,933 patients aged 18 and under, consisting of 413,455 COVID-positive patients and 1,163,478 COVID-negative controls. Data were standardized according to the National Patient-Centered Clinical Research Network (PCORnet) Common Data Model to ensure consistency across the 29 participating healthcare institutions.

To ensure the validity of the comparison, the team employed propensity-score-based stratification. This statistical approach balanced the cohorts across various baseline confounders, including age, sex, race, obesity, and pre-existing chronic conditions. A stratified Poisson regression model was used to calculate adjusted risk ratios (aRR). Furthermore, the researchers utilized 36 "negative control outcomes"—conditions unrelated to COVID-19—to calibrate the results and account for potential residual bias.

Outcomes were categorized into nine predefined GI symptoms (e.g., abdominal pain, bloating, nausea) and disorders (e.g., GERD, IBS) based on ICD-10-CM codes.

Key Findings

Persistent and Increasing Risk

One of the most significant findings was that the risk for GI issues did not diminish quickly. In fact, the risk was slightly higher in the chronic phase (aRR 1.28) than in the post-acute phase (aRR 1.25). This indicates that GI complications are not merely slow-resolving acute symptoms but can persist or even emerge long after the initial respiratory symptoms of COVID-19 have vanished.

Demographic and Clinical Risk Factors

  • Age: Children under the age of five were found to be at the highest risk for developing GI disorders and symptoms compared to older pediatric groups.
  • Severity of Infection: A "dose-response" relationship was observed; children who required hospitalization or ICU admission during the acute phase of COVID-19 faced a progressively higher risk of subsequent GI-related medical visits.

Specific Symptoms and Disorders

The study noted a statistically significant increase in risk across nearly all measured GI categories:

  • Overall Incidence: 8.64% of COVID-positive children experienced at least one GI issue in the post-acute phase (vs. 6.85% of controls), rising to 12.60% in the chronic phase (vs. 9.47% of controls).
  • High-Risk Symptoms: During the post-acute phase, the highest increased risks were seen in diarrhea (aRR 1.40), vomiting (aRR 1.33), and bloating (aRR 1.27).
  • Abdominal Pain: This remained a dominant and persistent issue, with an aRR of 1.14 in the post-acute phase and 1.24 in the chronic phase.
  • GERD: The risk of Gastroesophageal reflux disease was significantly elevated (aRR 1.19).

Notably, Irritable Bowel Syndrome (IBS) did not show a significant increase during the post-acute phase. This is likely due to the Rome IV diagnostic criteria, which require symptoms to persist for at least six months before a formal diagnosis can be made, making it difficult to capture in the early post-acute window.

Discussion

The biological mechanisms driving these persistent GI symptoms may involve the high expression of ACE2 receptors in the small intestine, which serve as the primary entry point for SARS-CoV-2. The researchers also suggest that potential shifts in the gut microbiome following infection could contribute to long-term dysfunction.

While the study provides robust evidence, it is limited by its reliance on Electronic Health Records (EHR). Potential misclassification of uninfected controls (who may have had undocumented infections) and unmeasured confounders are inherent risks in such retrospective designs. Additionally, the 6-month diagnostic window for IBS complicates assessment during the early post-acute phase.

Conclusion

This large-scale study confirms that SARS-CoV-2 infection significantly increases the risk of long-term GI complications in children for up to two years post-infection. The findings underscore the importance of including GI assessments in the clinical management of pediatric PASC. Future research should focus on the underlying pathophysiology, including viral persistence in the gut and microbiome changes, to develop targeted therapeutic interventions for affected children.

Summary updated

Abstract

In the post-acute phase or chronic phase of COVID-19, the risk of GI symptoms and disorders was increased for COVID-positive patients in the pediatric population.
BibTeX
@misc{zhang2024pediatric,
  author = {Dazheng Zhang and Ronen Stein and Yiwen Lu and Ting Zhou and Yuqing Lei and Lu Li and Jiajie Chen and Jonathan Arnold and Michael J. Becich and Elizabeth A. Chrischilles and Cynthia H. Chuang and Dimitri Christakis and Daniel Fort and Carol Geary and Mady Hornig and Rainu Kaushal and David Liebovitz and Abu Saleh Mohammad Mosa and Hiroki Morizono and Parsa Mirhaji and Jennifer L. Dotson and Claudia Pulgarin and Marion R. Sills and Srinivasan Suresh and David A. Williams and Robert N. Baldassano and Christopher B. Forrest and Yong Chen},
  title = {{Pediatric Gastrointestinal Outcomes During the Post-Acute Phase of COVID-19: Findings from RECOVER Initiative from 29 Hospitals in the US}},
  year = {2024},
  doi = {10.1101/2024.05.21.24307699},
  howpublished = {medRxiv},
}
Figure